News Archive

Lung cancer, like many other neoplasms, is increasingly recognized as consisting of a host of relatively rare genomic subsets, each of which may require treatment with a different targeted drug. The Lung-MAP trial models a way to efficiently study a large number of these rare subsets under one master protocol.